OBJECTIVE：To provide reference for performance evaluation of pharmaceutical care for clinical pharmacists. METHODS：Based on literature review ，weighted TOPSIS method was used to formulate a performance evaluation system of pharmaceutical care. The performance of 120 pharmaceutical care work of 5 clinical pharmacists in our hospital from Jan. 2017 to Dec. 2018 was evaluated. RESULTS ：The performance evaluation detailed rules of clinical pharmacists ’pharmaceutical care work were successfully constructed ，including pharmaceutical ward round ，medication education ，medication consultation and pharmacy consultation，with a total of 17 evaluation indicators. Among 120 cases，there were 21 cases with relative approach degree ＞0.6 （17.5％）；73 cases had relative approach degree between 0.5 and ＜0.6（60.8％）；26 cases had relative approach degree between 0.4 and ＜0.5（21.7％）. The major problem was that the participation of clinical pharmacists in muti-disciplinary treatment ，the approval of scientific research fund projects were insufficient and not much paper was written. CONCLUSIONS ：The performance evaluation system of clinical pharmacists ’pharmaceutical care work based on weighted TOPSIS method is normative and reasonable，and it can be used in the evaluation of clinical pharmacists ’pharmaceutical care work . The results suggest that there are some defects in the performance of clinical pharmacists ’pharmaceutical care work in our hospital ，which need to be improved.

BACKGROUNDCigarette smoke induced airway inflammation plays a role in pathogenesis of airway inflammation. Resolvin-D1 derived from omega-3 polyunsaturated fatty acids is an endogenous anti-inflammatory and proresolving lipid mediator. Resolvin-D1 ameliorated inflammatory responses in lung injury, asthma, peritonitis and atherosclerosis. We investigated whether resolvin-D1 suppressed the productions of chemokines and oxidative stress induced by cigarette smoke extract (CSE) in vitro and its possible mechanism.

METHODSWe examined the proinflammatory chemokine interleukin-8 and hydrogen peroxide (H2O2) productions induced by CSE in 16 human bronchial epithelial (16HBE) cells after resolvin-D1 treatment and their mechanisms. 16HBE cells were treated with resolvin-D1 at up to 10 nmol/L, for 30 minutes before CSE up to 16% (v/v) exposure. Release of interlukin-8 proteins was assessed by enzyme linked immunosort assay (ELISA) and its mRNA level by RT-PCR. We evaluated extracellular H2O2 expression in the supernatant. Phosphorylation of NF-κB/p65 and degradation of I-κB in 16HBE cells were determined by Western blotting analysis and NF-κB DNA binding activity by electrophoretic mobility shift assay (EMSA).

RESULTS16HBE cells treated with 8% CSE showed significantly higher interlukin-8 production. Resolvin-D1 pretreatment inhibited CSE induced interlukin-8 production (mRNA and protein) in a dose and time dependent manner. Extracellular H2O2 level decreased after resolvin-D1 treatment. Resolvin-D1 attenuated CSE triggered I-κB degradation and NF-κB/p65 activation dose dependently and inhibited NF-κB DNA binding activity.

CONCLUSIONResolvin-D1 inhibits CSE induced interlukin-8 and H2O2 production in 16HBE cells by modulating NF-κB activation and has therapeutic potential for pulmonary inflammation.

Blotting, Western ; Cell Line ; Cell Survival ; drug effects ; Docosahexaenoic Acids ; pharmacology ; Electrophoretic Mobility Shift Assay ; Enzyme-Linked Immunosorbent Assay ; Humans ; Hydrogen Peroxide ; metabolism ; Interleukin-8 ; metabolism ; NF-kappa B ; metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Smoking ; adverse effects